IDSA guideline strongly recommends the 2025-2026 COVID-19 vaccine for all immunocompromised individuals aged ≥6 months; 7 observational studies associated vaccination with 33%-56% lower hospitalisation. Certainty was moderate for benefit, low for harm.
Guideline
Nellore et al. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients